Merck KGaA presents the advancements in bioprocessing through high productivity membrane chromatography, aiming to transform monoclonal antibody manufacturing by enhancing speed, flexibility, quality, and cost-efficiency. The natrix® membrane technology enables a fully single-use process, aligning with modern demands for reduced facility costs and improved operational agility. The document outlines performance targets to achieve significant reductions in manufacturing expenses while maintaining quality standards for biologics.